Major US demand for obesity drug obesity Wegovy – which has led to delivery problems for Novo Nordisk – mean that the Danish pharmaceutical company will not begin new launches of the medication before a year's time at the earliest, Novo tells MedWatch in an email.
"We are currently assessing how we can increase production capacity and continue to global rollout following approval from public authorities outside the US. For the moment, the US is expected to take the accessible production capacity for Wegovy, and that means new launches will occur in the second half of 2022 at the earliest," the company's press unit writes.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.